Global IgA Nephropathy (IgAN) Market Size Exceed To USD 0.36 Billion by 2035| CAGR of 10.72%: Market Growth Report

• As per Spherical Insights & Consulting, The Global IgA Nephropathy (IgAN) Market Size is Expected to Grow from USD 0.13 Billion in 2025 to USD 0.36 Billion by 2035, at a CAGR of 10.72% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.
• IgA nephropathy (IgAN) has a global incidence of around 2.5 cases per 100,000 people annually, with evidence suggesting a rising trend over time.
• Its occurrence varies widely across geographic regions, being most prevalent in East Asia, followed by Europe, and least frequent in Africa.
• The leading IgA Nephropathy (IgAN) Market Companies such as Novartis, Takeda, Otsuka Pharmaceutical, GlaxoSmithKline (GSK), Johnson & Johnson, Pfizer, AstraZeneca, Amgen, Bayer, Eli Lilly, Sanofi, Roche, AbbVie, Merck, Bristol Myers Squibb, and Others.

 

IgA Nephropathy (IgAN) Treatment Market: Understanding and Treatment Algorithm:

IgA nephropathy (IgAN) is a kidney disease caused by the build-up of immunoglobulin A in the glomeruli, leading to inflammation and potential long-term damage. It often develops after infections and commonly presents with blood in the urine, proteinuria, and high blood pressure. The disease progresses at varying rates and can eventually lead to kidney failure.

 

IgA Nephropathy (IgAN) Diagnosis:

IgA nephropathy is diagnosed through a combination of clinical findings and laboratory tests. Urinalysis typically shows blood and protein in the urine. Blood tests assess kidney function. A definitive diagnosis requires a kidney biopsy, which reveals IgA deposits in the glomeruli using immunofluorescence. Biopsy also helps evaluate the extent of kidney damage and guide management.

 

IgA Nephropathy (IgAN) Treatment

Treatment for IgA nephropathy aims to slow disease progression and manage symptoms. Blood pressure control using ACE inhibitors or ARBs is essential, especially with proteinuria. Lifestyle changes like reduced salt and protein intake help. In selected cases, corticosteroids or other immunosuppressants are used. Advanced disease may require dialysis or kidney transplantation in end-stage renal failure.

 

IgA Nephropathy (IgAN) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of IgA Nephropathy (IgAN), Gender-specific Diagnosed Incidence of IgA Nephropathy (IgAN), Type-specific Diagnosed Incidence of IgA Nephropathy (IgAN), Age-specific Diagnosed Incidence of IgA Nephropathy (IgAN), Diagnosed Incident Population based on Primary Site of IgA Nephropathy (IgAN), and Diagnosed Incident Population based on Histologic Classification of IgA Nephropathy (IgAN) Tumour in the global market covering North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of IgA nephropathy (IgAN) epidemiology in major markets worldwide.

 

Country Wise- IgA Nephropathy (IgAN) Multiforme Epidemiology

• The epidemiology segment provides IgA Nephropathy (IgAN) prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

• IgA nephropathy (IgAN) represents a notable proportion of kidney biopsies across Asia, comprising 12% in Taiwan, 24% in China, 31% in Japan, and 41% in South Korea. Additionally, among primary glomerular diseases, IgAN accounts for 26% of biopsies in Taiwan, 27% in China, and 52% in South Korea.

 

• In Australia and New Zealand, IgA nephropathy (IgAN) frequency in kidney biopsies ranges from 13% to 34%. South America shows lower rates, around 6%, though a Brazilian study reported 20%. In Africa, IgAN is rare, representing about 3 6% of primary glomerular disease biopsies, reflecting regional variations and limited data availability.

 

IgA Nephropathy (IgAN) Recent Developments:

• In April 2024, Vertex Pharmaceuticals announced its acquisition of Alpine Immune Sciences for approximately USD 4.9 billion in cash, marking its largest ever deal. The acquisition provided Vertex access to Alpine's lead candidate, povetacicept, a dual BAFF/APRIL antagonist in mid-stage development for IgA nephropathy. Povetacicept demonstrated over 60% reduction in proteinuria and stable renal function in Phase II trials.

 

IgA Nephropathy (IgAN) Marketed Drugs:

• Tarpeyo: Calliditas Therapeutics

Tarpeyo (budesonide) is a targeted-release oral corticosteroid designed to reduce kidney inflammation by delivering medication directly to the gut associated lymphoid tissue. It is FDA approved for treating adults with IgA nephropathy at risk of rapid disease progression.

 

• Filspari: Travere Therapeutics

Filspari (sparsentan) is a dual endothelin receptor and angiotensin receptor blocker that reduces proteinuria and protects kidney function. It is FDA approved for IgA nephropathy patients at risk of progression.

 

• Vanrafia (Atrasentan): Novartis

Vanrafia is a selective endothelin A receptor antagonist that lowers proteinuria and slows kidney damage in IgA nephropathy. It received FDA accelerated approval for the treatment of patients at risk of rapid progression.

 

IgA Nephropathy (IgAN): Emerging Therapies

• Povetacicept: Povetacicept is a dual BAFF/APRIL inhibitor currently in late stage clinical trials for IgA nephropathy. By targeting key B cell survival factors, it aims to reduce the formation of pathogenic IgA immune complexes, decrease proteinuria, and slow kidney damage progression.
• Atacicept: Atacicept is a fusion protein that blocks both BAFF and APRIL, reducing B-cell activity. It is in Phase II/III trials for IgAN, showing promise in lowering proteinuria and preserving kidney function.
• Telitacicept: Telitacicept, an APRIL inhibitor, is under investigation in Phase III trials for IgAN. It aims to modulate the immune response and reduce kidney inflammation associated with the disease.
• Sefaxersen (IONIS FB LRx): Sefaxersen is an antisense oligonucleotide targeting complement factor B, designed to inhibit the alternative complement pathway involved in IgAN progression. It is currently in Phase 2/3 clinical trials.
• Nefecon: Nefecon is a targeted release formulation of budesonide, designed to deliver corticosteroids to the gut-associated lymphoid tissue. It has shown efficacy in reducing proteinuria in IgAN patients and is approved in some markets.

 

IgA Nephropathy (IgAN) Market Outlook

• The IgA nephropathy (IgAN) market defines the development, production, and commercialization of therapies aimed at diagnosing, managing, and treating IgAN, a chronic kidney disease characterized by IgA deposits causing inflammation and kidney damage. The market includes drugs, diagnostics, and supportive care solutions.
• Rising prevalence of IgA nephropathy globally and growing awareness among healthcare providers drive market growth. Additionally, advances in targeted therapies and increasing investment in kidney disease research fuel demand for innovative treatments.
• Expanding emerging therapies targeting underlying disease mechanisms offer significant market opportunities. Increasing screening programs and unmet needs in early diagnosis and treatment in underserved regions also present growth potential.
• Governments worldwide are increasing funding for kidney disease screening and treatment programs to improve early diagnosis and access to care. Initiatives like subsidized dialysis and insurance coverage aim to reduce the financial burden on patients with IgA nephropathy.
• Limited early diagnosis and lack of curative treatments remain major challenges in managing IgA nephropathy effectively.
• The IgA nephropathy market is projected to grow steadily, driven by rising prevalence, innovative therapies, and expanding healthcare investments globally.

 

IgA Nephropathy (IgAN) Market Segmentation

By Diagnosis:

• Iothalamate Clearance Test
• Kidney Biopsy
• Blood Tests
• Urine Tests

 

Kidney Biopsy dominates the IgA nephropathy diagnosis segment due to its ability to provide definitive confirmation by directly visualizing IgA deposits and kidney damage. While blood and urine tests offer supportive information, biopsy remains the gold standard for accurate diagnosis, prognosis assessment, and treatment planning, making it essential despite its invasiveness and cost.

 

By Disease Type:

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

 

Primary IgA Nephropathy dominates the market due to its higher prevalence as a standalone kidney disorder. Secondary IgAN, linked to other diseases like liver or autoimmune conditions, is less common. The focus on primary IgAN drives research and treatment development, making it the key segment influencing market growth and therapeutic advancements.

 

 

Regional Segment Analysis of the IgA Nephropathy (IgAN) Market

The Asia Pacific region dominates the IgA Nephropathy (IgAN) market with the largest share, driven primarily by its high disease prevalence in countries like China, Japan, and South Korea. Rapid improvements in healthcare infrastructure, increasing government support, and growing awareness about kidney diseases contribute significantly. Additionally, expanding diagnostic capabilities and rising patient populations further accelerate market growth in this region.

 

North America is the fastest-growing IgAN market, driven by significant investments in healthcare research and development. Rising awareness about kidney diseases, better diagnostic adoption, and the introduction of innovative therapies fuel market expansion. Strong regulatory support and high healthcare spending accelerate growth in this region.

 

IgA Nephropathy (IgAN) Market Key Companies

• Novartis
• Vertex Pharmaceuticals
• Otsuka Pharmaceutical
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Pfizer
• AstraZeneca
• Amgen
• Bayer
• Eli Lilly
• Sanofi
• Roche
• AbbVie
• Merck
• Bristol-Myers Squibb
• Others

 

IgA Nephropathy (IgAN) Therapeutics Market Report Scope

• The IgA Nephropathy (IgAN) therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into IgA Nephropathy (IgAN)’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging IgA Nephropathy (IgAN) therapies is provided, including an evaluation of new treatments expected to influence the current IgA Nephropathy (IgAN) treatment market landscape.
• The report includes a detailed review of the IgA Nephropathy (IgAN) therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based IgA Nephropathy (IgAN) Market Forecasting report offers valuable insights into trends shaping the global IgA Nephropathy (IgAN) market, helping to develop effective business strategies.

 

IgA Nephropathy (IgAN) Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• IgA Nephropathy (IgAN) Therapeutic Approaches in IgA Nephropathy (IgAN)
• Review Of Drugs in Development for IgA Nephropathy (IgAN)
• Market, Growth, and Trends in IgA Nephropathy (IgAN)
• Market Opportunities in IgA Nephropathy (IgAN) Treatment
• Effects Of Future Therapies on IgA Nephropathy (IgAN) Treatment.

 

IgA Nephropathy (IgAN) Treatment Market Report Key Strengths

• 15 Years IgA Nephropathy (IgAN) Market Forecast
• Global Coverage
• IgA Nephropathy (IgAN) Epidemiology Segmentation
• Key Cross Competition

 

IgA Nephropathy (IgAN) Treatment Market Report Assessment

• Present Practices in the IgA Nephropathy (IgAN) Treatment Market
• Review of Investigational IgA Nephropathy (IgAN) Drugs
• Attractiveness of the IgA Nephropathy (IgAN) Drug Market
• IgA Nephropathy (IgAN) Market Drivers
• IgA Nephropathy (IgAN) Market Barriers
• SWOT
• Attribute Analysis

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the IgA nephropathy (IgAN) market based on the below-mentioned segments:

 

Global IgA Nephropathy (IgAN) Market, By Diagnosis

• Iothalamate Clearance Test
• Kidney Biopsy
• Blood Tests
• Urine Tests

 

Global IgA Nephropathy (IgAN) Market, By Disease Type

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

 

Global IgA Nephropathy (IgAN) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa